Alzheimer's Disease Research Guide: Animal Models for Understanding Mechanisms and Medications
Autor Takaomi C. Saidoen Limba Engleză Paperback – 5 aug 2024
Written by world renowned expert in Alzheimer’s research, this book is a valuable resource for all researchers.
- Reviews why familial Alzheimer’s disease is vital to understanding sporadic Alzheimer’s disease
- Describes the latest “game changer” animal models of Alzheimer's disease and frontotemporal dementia in detail
- Explains how various Alzheimer’s disease medications have failed clinical trials
- Discusses pros and cons of therapeutic antibodies, lecanemab and donanemab, that were recently found to be effective in recent clinical trials
- Details the application of genome editing as a treatment for familial Alzheimer’s disease
- Proposes publishing “Journal of Negative Data” for the days of generative AI-assisted publication, AI being unable to distinguish between reproducible and unreproducible data, particularly important in Alzheimer’s research
Preț: 709.04 lei
Preț vechi: 779.17 lei
-9% Nou
Puncte Express: 1064
Preț estimativ în valută:
135.71€ • 141.14$ • 113.72£
135.71€ • 141.14$ • 113.72£
Carte tipărită la comandă
Livrare economică 06-20 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780443289798
ISBN-10: 0443289794
Pagini: 300
Dimensiuni: 152 x 229 mm
Editura: ELSEVIER SCIENCE
ISBN-10: 0443289794
Pagini: 300
Dimensiuni: 152 x 229 mm
Editura: ELSEVIER SCIENCE
Cuprins
1. Introduction: Collaboration and Competition Together to Maximize the Velocity of Research and Development
2. Pathological Chronology and Pathological Biochemistry: The Beginning of The Beginning
3. Human Genetics: Establishment of Cause-And-Effect Relationships
4. Two Major Culprits: Amyloidogenic Aß And Non-Amyloidogenic Tau
5. Exact relationship between Aβ40 and Aβ42
6. Metabolism of Aβ: Catabolic and glimphatic systems
7. Biology of time: Temporal distance between cause and effect
8. 1st generation animal moβdels of Aβ amyoloidosis: Pros and cons of overexpression paradigm
9. Creation of single APPKNOCK-IN mouse models and of single MAPTNOKCK-IN models: Demonstration of AB-Tau axis
10. Application of Mouse Models to the experimental studies of AD
11. Neuroinflammation: Microgliosis and Astrocytosis in the days of microscopic omics
12. Central and peripheral nervous system, immune systems and digestive system: AD as a systemic disorder
13. Failure of more than 400 candidate medications in clinical trials before 2020
14. Therapeutic antibodies as a Wright brothers' airplane: Clinical proof-of-concept
15. Biomarkers for presymptomatic diagnosis and prognosis
16. Targeting somatostatin receptor heterodimer for developing safe, effective and ineffective and inexpensive medications
17. Application of genome editing to the treatment of familial AD
18. Identifying significant and insignificant publications: Prelude for chapter XIX
19. Journal of negative data for the days of generative AI-assisted publication
20. Conclusions
2. Pathological Chronology and Pathological Biochemistry: The Beginning of The Beginning
3. Human Genetics: Establishment of Cause-And-Effect Relationships
4. Two Major Culprits: Amyloidogenic Aß And Non-Amyloidogenic Tau
5. Exact relationship between Aβ40 and Aβ42
6. Metabolism of Aβ: Catabolic and glimphatic systems
7. Biology of time: Temporal distance between cause and effect
8. 1st generation animal moβdels of Aβ amyoloidosis: Pros and cons of overexpression paradigm
9. Creation of single APPKNOCK-IN mouse models and of single MAPTNOKCK-IN models: Demonstration of AB-Tau axis
10. Application of Mouse Models to the experimental studies of AD
11. Neuroinflammation: Microgliosis and Astrocytosis in the days of microscopic omics
12. Central and peripheral nervous system, immune systems and digestive system: AD as a systemic disorder
13. Failure of more than 400 candidate medications in clinical trials before 2020
14. Therapeutic antibodies as a Wright brothers' airplane: Clinical proof-of-concept
15. Biomarkers for presymptomatic diagnosis and prognosis
16. Targeting somatostatin receptor heterodimer for developing safe, effective and ineffective and inexpensive medications
17. Application of genome editing to the treatment of familial AD
18. Identifying significant and insignificant publications: Prelude for chapter XIX
19. Journal of negative data for the days of generative AI-assisted publication
20. Conclusions
Recenzii
"Disease -modifying drugs have been approved, and the research field for Alzheimer's disease is now entering a new stage. This book is relevant during such a time of transition. This inspiring book concentrates on the essence of fighting at the frontlines of Alzheimer’s research. In particular, it conveys the importance of focusing on one's own research from a long-term perspective." -- Kenichi Nagata, Designated Lecturer, Department of Functional Anatomy & Neuroscience, Nagoya University Graduate School of Medicine
"Written by a prominent leader in the Alzheimer’s disease research field, this book is a marvelous must-read guidebook for next generations interested in Alzheimer’s disease studies, especially in animal models of Alzheimer’s disease. Each chapter is written with historical emphasis and lively manner in such a way that readers can enjoy close dialogues with the author. This is the book I looked for 8 years ago when I started Alzheimer’s disease research!" -- Kei M Igarashi, Ph.D., Chancellor’s Fellow Associate Professor, Department of Anatomy and Neurobiology, University of California, Irvine
"Written by a prominent leader in the Alzheimer’s disease research field, this book is a marvelous must-read guidebook for next generations interested in Alzheimer’s disease studies, especially in animal models of Alzheimer’s disease. Each chapter is written with historical emphasis and lively manner in such a way that readers can enjoy close dialogues with the author. This is the book I looked for 8 years ago when I started Alzheimer’s disease research!" -- Kei M Igarashi, Ph.D., Chancellor’s Fellow Associate Professor, Department of Anatomy and Neurobiology, University of California, Irvine